October 28, 2016
Teva IBM join forces on finding new uses for drugs
IBM and Teva Pharmaceutical Industries Ltd., are expanding their global e-Health alliance to focus on the discovery of new treatment …
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
October 27, 2016
Newly approved drugs push Lilly’s revenues 5% up, but net income went 3% down
The world’s leading drugmaker Eli Lilly saw a decline in net income for the third…
October 27, 2016
Allergan to close down buying Motus, relamorelin goes to Phase 3 tests
Allergan on Thursday announced the results of Phase 2b study of the new gastroparesis…
October 27, 2016
Advanced Oncotherapy promotes Nicolas Serandour as new CEO
Advanced Oncotherapy has named Nicolas Serandour the new CEO…
October 26, 2016
AstraZeneca’s ovarian cancer tablets pass Phase III SOLO-2 trial
AstraZeneca’s Lynparza tablets against BRCA-mutated ovarian cancer have shown…
October 25, 2016
Bangladesh’s Beximco gets its second US FDA product approval
Bangladesh-based Beximco, the largest country’s pharmaceutcals exporter, has received its second US FDA …
October 24, 2016
Faron recruits patients for the Japanese Traumakine Phase III trial
Faron Pharmaceuticals (Faron), the clinical stage biopharmaceutical company, has recruited the first patient in the Japanese Phase III pivotal clinical trial for the…
October 20, 2016
Esperite starts developing inflammatory bowel disease therapies; Starts with Crohn`s disease
Esperite`s business unit The Cell Factory in collaboration with Women`s and Children`s Health Department of the University of Padua and the Padua University Hospital are developing therapies for inflammatory bowel disease (IBD) using extracellular vesicles (EVs).
October 20, 2016
Transgene announces €48 M rights issue, reports €1,1M operating revenue decrease
Transgene, a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, announced the launch and terms of a share capital increase with shareholders’ preferential subscription rights for a total gross amount of circa €48 million, issue premium included (the “Rights Issue”).
October 20, 2016
Genomic Vision presents the initial results of the pilot study undertaken with quest diagnostics in spinal muscular atrophy
Genomic Vision, DNA molecular combing specialist that develops tests for the diagnostics market and tools for the life sciences research market, has presented, at the Annual Meeting of the American Society of Human Genetics, the initial results of the pilot study undertaken with Quest Diagnostics that aims to identify a biomarker to improve genetic counseling for Spinal Muscular Atrophy (SMA) in the African-American population.